Menu
Washingtoner
  • Home
  • Business
  • Construction
  • Technology
  • Arts
  • Health
  • Property
  • Software
  • Real Estate
Washingtoner

Myosana Therapeutics Raises $5 Million in Seed Funding
Washingtoner/10205303

Trending...
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • LIB and Nidec Rejoin Forces for Giant TH-0098 Temperature Humidity Test Chamber
  • Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
SEATTLE--(BUSINESS WIRE)--Myosana Therapeutics, Inc., pioneer of a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases, today announced the completion of a seed funding round totaling over $5 million led by investor John Ballantyne, Ph.D. The capital will go toward developing Myosana's platform with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025.

"Built on decades of expertise in neuromuscular diseases, Myosana's muscle-specific non-viral gene therapy platform is poised to change the way patients are treated for neuromuscular and cardiac diseases," said Ballantyne, Cofounder and former longtime CSO of Biologics CDMO-Aldevron, and a Founder of therapeutic delivery system developer Agathos. "Myosana's progress building on the platform's promising in vivo data is an essential next step. I'm excited to partner with the company as it pushes ahead toward a therapy that will reach patients and improve their lives."

New investments from the Muscular Dystrophy Association and Parent Project Muscular Dystrophy (PPMD) rounded out the seed round, building on capital from original Myosana investor CureDuchenne Ventures and early investor PPMD a year later.

More on Washingtoner
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
  • Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Arcadis welcomes transportation leader Greg Spotts to advance mobility in Seattle and California

Completion of this major funding round comes just as Myosana has appointed its new CEO, Dr. Matthew Lumley. A board member since 2021, Lumley is a physician scientist who has spent nearly two decades in academic medicine and drug development, cultivating expertise in translational medicine and early clinical development in complex pediatric diseases. Lumley is also the father of a son with Duchenne muscular dystrophy. In his role on Myosana's Board of Directors, Lumley has been intimately involved in raising seed funding and advancing the platform.

"Dr. Ballantyne's expertise in the nucleic acid production and delivery spaces builds credibility in our approach. His investment, alongside our nonprofit partners, will go directly to platform optimization and the identification of a development candidate for Duchenne muscular dystrophy in the next 18-24 months," said Lumley. "As proof of principle for the platform, success in treating Duchenne would open up opportunities for Myosana to target a large range of neuromuscular and cardiac diseases."

Alongside his role as CEO of Myosana, Lumley is a Venture Partner at Medicxi, a life sciences-focused venture capital firm where he is involved in the formation and financing of biotechnology companies across the full drug development continuum. His recent roles include Senior Director of Rare Disease Clinical Development at Moderna and Medical Director of Rare Diseases at Pfizer.

About Myosana Therapeutics

Myosana Therapeutics, Inc., has pioneered a muscle-specific non-viral gene therapy platform for neuromuscular and cardiac diseases. Based on this platform, the company is developing new gene therapies that will potentially transform progressive neuromuscular and cardiac diseases, increasing longevity and improving quality of life. Myosana's first clinical candidate from the platform will be delivery of full-length dystrophin as a therapy for Duchenne muscular dystrophy.

More on Washingtoner
  • Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
  • SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
  • TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas

Myosana's esteemed leadership team includes cofounders Stan Froehner, Ph.D., and Nick Whitehead, Ph.D., both internationally known experts in neuromuscular disease from the University of Washington, whose decades-long careers are marked by significant milestones. Dr. Froehner discovered the syntrophin proteins in muscle's dystrophin complex and developed several pre-clinical treatments for muscular dystrophy. Dr. Whitehead has uncovered mechanisms of muscle weakness in Duchenne muscular dystrophy and developed Myosana's innovative non-viral platform. The platform overcomes the significant limitations of viral vector-delivered gene therapy for muscle disease by providing targeted muscle delivery, large gene capacity, repeat dosing, and immune neutrality.

To learn more and follow Myosana's progress toward its first clinical development candidate, visit us at www.myosanatherapeutics.com.

Contacts

Kara Stephens-Weaver
407-765-1185
kara.stephens-weaver@precisionvh.com
Filed Under: Business

Show All News | Report Violation

1 Comment
1000 characters max.

  • unity asset store.:
    Build real-time 3D projects for various industries across games, animation, automotive, architecture, and more with Unity Asset Store. Start creating with Unity today!
Latest on Washingtoner
  • Spokane: National Night Out Against Crime is August 5th
  • Easton & Easton, LLP Files Suit Against The Dwelling Place Anaheim & Vineyard USA Over Abuse Allegations
  • AI Visibility: The Key to Beating Google's AI Overviews and Regaining Traffic
  • Stuck Doing Math or Figuring Out Life's Numbers? Calculator.now Makes It Stupidly Simple
  • Spokane: Mayor Brown Urges Federal Lawmakers to Save the Community Development Block Grant (CDBG) Program
  • Colbert Packaging Announces WBENC Recognition
  • DivX Empowers Media Enthusiasts with Free Expert Guides for Advanced MP4 Management
  • Assent Expands Executive Team to Accelerate Global Growth & Innovation
  • The World's Largest Green Economic Revolution Emerges as Nature, Tech, and Finance Converge
  • Vinnetwork Unveils Decentralized AI Platform with Vinnetwork(VIN) Token to Challenge Tech Giants' Data Monopoly
  • Centennial Flyers to Become Colorado's First Launch Customer for All-Electric B23 Energic Aircraft
  • Spokane Firefighters Battle 15 Suspicious Fires in 36 Hours
  • Pyro Marketing Opens New Digital Marketing Company to Power Growth for Fitness and Ecommerce Brands
  • Dr. John Salerno of Salerno Wellness Introduces Their New Full Body Capsule for Advanced LED Light Therapy Patient Treatments
  • Alaska Air Group announces webcast of second-quarter 2025 financial results
  • $14M Expansion Deal with Famed David Lloyd Highlights Rebrand of Sports, Entertainment and Gaming Innovation by AI Driven, Online Fan Engagement Co
  • Heartfelt Dreams Foundation Launches Campaign to Build CHD Hospital
  • Radarsign Tackles Intersection Safety with Launch of Grid-Free Solar LED Stop Sign
  • Miami Real Estate Agent Drastically Increases Interest In Homes
  • Adostics & Genmega Announce the Introduction of A-POD
_catLbl0 _catLbl1

Popular on Washingtoner

  • ASI Accelerates iMIS® Innovation by Acquiring CSI's Product Suite and Expert Team - 220
  • Keebos Launches New Universal Pearl Strap That Attaches to Any Phone Case - 208
  • Integris Composites Joins Paris Air Show at USA Pavilion - 189
  • Sploot Vets and DeepScan Launch Exclusive Regional U.S. Partnership to Bring Breakthrough Pet DNA Test to Market - 145
  • Evluma and LED Roadway Lighting Ltd. Join Forces to Drive Innovation - 140
  • purelyIV Blog Named One of the Top 45 IV Therapy Blogs by Feedspot - 129
  • GMO Miner: Creating a simple, efficient and reliable new cloud mining experience - 126
  • Exciting News: Pivotal Health Solutions Acquires Revolutionary Portable Parallel Bars - 122
  • Pregis Shares 2024 Sustainability Report Highlighting Progress in Circular Product Innovation, Emissions Accountability, and Global Impact - 121
  • High Profile Gateway Race Events With Strong Brand Exposure Plus Sponsorship in Female Motorsports; $100 Million Financing Unlocked: Lottery.com - 111

Similar on Washingtoner

  • Hire a Business Plan Writer: What to Expect and Why It's Worth It
  • Fastest Growing Staffings Firms
  • Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
  • $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
  • Arcadis welcomes transportation leader Greg Spotts to advance mobility in Seattle and California
  • $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
  • Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
  • The Blue Luna Encourages Local Schools to Take Steps to Enhance Safety for Students and Staff
  • Smart Resnse Unveils Smart Resnse(SRMS) Token-Powered AI Orchestration Platform to Revolutionize Multi-Billion Dollar Market
  • Cover Girl Finalist Teisha Mechetti Questions Legitimacy of Inked Originals Competition, Demands Transparency
Copyright © 2025 washingtoner.com | Terms of Service | Privacy Policy | Contact Us | Contribute